New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Lilly's (LLY) Risk/Reward Looks Good Ahead of Q3 Report - BMO
October 16, 2015 10:45 AM EDTBMO is out with positive commentary on Eli Lilly (NYSE: LLY), saying that the risk/reward on the stock looks good at this point, but not enough to change the firm's rating.
Alex Arfaei said, In 3Q15, we expect a ~9% bottom line beat... More
Eli Lilly & Co. (LLY), Boehringer Announces U.S. Availability of Synjardy Tabs
October 14, 2015 8:31 AM EDTBoehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) announced that Synjardy® (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States. The U.S. Food and Drug Administration (FDA) approved SYNJARDY at the end of August as an adjunct to diet and exercise to improve glycemic control in adults with T2D who are not adequately controlled on a regimen containing empagliflozin or metformin alone, or in patients... More
